The effects of fluorouracil, epirubicin, and cyclophosphamide (FEC60) on the intestinal barrier function and gut peptides in breast cancer patients: an observational study

被引：0
|
作者：
Francesco Russo
Michele Linsalata
Caterina Clemente
Benedetta D’Attoma
Antonella Orlando
Giovanna Campanella
Francesco Giotta
Giuseppe Riezzo
机构：
[1] National Institute for Digestive Diseases I.R.C.C.S. “Saverio de Bellis”,Laboratory of Experimental Biochemistry
[2] Medical Oncology Unit I.R.C.C.S. “Saverio de Bellis”,Laboratory of Experimental Pathophysiology
[3] Castellana Grotte,undefined
[4] Medical Oncology Unit I.R.C.C.S. “Giovanni Paolo II”,undefined
[5] National Institute for Digestive Diseases I.R.C.C.S. “Saverio de Bellis”,undefined
[6] Castellana Grotte,undefined
来源：
BMC Cancer | / 13卷
关键词：
Breast cancer; Chemotherapy-induced diarrhea; Epidermal growth factor; Intestinal permeability; Ghrelin; Glucagon-like peptide 2; Gut peptides; Zonulin;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [41] Dose-finding phase I and pharmacokinetic study of capecitabine (xeloda) in combination with epirubicin and cyclophosphamide (CEX) in patients with inoperable or metastatic breast cancer
    Saji, Shigehira
    Toi, Masakazu
    Morita, Satoshi
    Iwata, Hiroji
    Ito, Yoshinori
    Ohno, Shinji
    Kobayashi, Tadashi
    Hozumi, Yasuo
    Sakamoto, Junichi
    ONCOLOGY, 2007, 72 (5-6) : 330 - 337
  • [42] Phase II study of docetaxel in combination with epirubicin and protracted venous infusion 5-fluorouracil (ETF) in patients with recurrent or metastatic breast cancer. A Yorkshire breast cancer research group study
    A C Humphreys
    J Dent
    S Rodwell
    S M Crawford
    J K Joffe
    C Bradley
    D Dodwell
    T J Perren
    British Journal of Cancer, 2004, 90 : 2131 - 2134
  • [43] Phase II study of docetaxel in combination with epirubicin and protracted venous infusion 5-fluorouracil (ETF) in patients with recurrent or metastatic breast cancer. A Yorkshire breast cancer research group study
    Humphreys, A
    Dent, J
    Rodwell, S
    Crawford, SM
    Joffe, JK
    Bradley, C
    Dodwell, D
    Perren, TJ
    BRITISH JOURNAL OF CANCER, 2004, 90 (11) : 2131 - 2134
  • [44] Effect of GSTP1 and ABCC4 gene polymorphisms on response and toxicity of cyclophosphamide- epirubicin-5-fluorouracil-based chemotherapy in Bangladeshi breast cancer patients
    Islam, Md. Siddiqul
    Islam, Mohammad Safiqul
    Parvin, Salma
    Ahmed, Maizbah Uddin
    Bin Sayeed, Muhammad Shahdaat
    Uddin, Mir Muhammad Nasir
    Hussain, Syed Md Akram
    Hasnat, Abul
    TUMOR BIOLOGY, 2015, 36 (07) : 5451 - 5457
  • [45] A phase III adjuvant randomised trial of 6 cycles of 5-fluorouracil-epirubicine-cyclophosphamide (FEC100) versus 4 FEC 100 followed by 4 Taxol (FEC-T) in node positive breast cancer patients (Trial B2000)
    Delbaldo, C.
    Serin, D.
    Mousseau, M.
    Greget, S.
    Audhuy, B.
    Priou, F.
    Berdah, J. F.
    Teissier, E.
    Laplaige, P.
    Zelek, L.
    Quinaux, E.
    Buyse, M.
    Piedbois, P.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 (01) : 23 - 30
  • [46] Short term quality of life with epirubicin-fluorouracil-cyclophosphamid (FEC) and sequential epirubicin/cyclophosphamid-docetaxel (EC-DOC) chemotherapy in patients with primary breast cancer - Results from the prospective multi-center randomized ADEBAR trial
    Schwentner, Lukas
    Harbeck, Nadia
    Singer, Susanne
    Eichler, Martin
    Rack, Brigitte
    Forstbauer, Helmut
    Wischnik, Arthur
    Scholz, Christoph
    Huober, Jens
    Friedl, Thomas W. P.
    Weissenbacher, Tobias
    Haertl, Kristin
    Kiechle, Marion
    Janni, Wolfgang
    Fink, Visnja
    BREAST, 2016, 27 : 69 - 77
  • [47] Preliminary results of a longitudinal study of changes in cognitive function in breast cancer patients undergoing chemotherapy with doxorubicin and cyclophosphamide
    Jansen, Catherine E.
    Dodd, Marylin J.
    Miaskowski, Christine A.
    Dowling, Glenna A.
    Kramer, Joel
    PSYCHO-ONCOLOGY, 2008, 17 (12) : 1189 - 1195
  • [48] Feasibility Study of Nanoparticle Albumin-Bound-Paclitaxel and S-1 Followed by Epirubicin/Cyclophosphamide as Neoadjuvant Chemotherapy in Patients With Operable Breast Cancer: A Prospective Study
    Seki, Hirohito
    Higeta, Kaori
    Sakurai, Takashi
    Sakurada, Akihisa
    Kinoshita, Tetsuhiko
    Shimizu, Ken
    CLINICAL BREAST CANCER, 2022, 22 (03) : 235 - 243
  • [49] The Add-On Effect of Fluorouracil, Epirubicin, and Cyclophosphamide Regimens for Neoadjuvant Chemotherapy in Human Epidermal Receptor 2 (HER2)-Positive Breast Cancer: A Single-Center Retrospective Study
    Yoshino, Ryusei
    Yoshida, Nana
    Ujiie, Nanami
    Nakatsubo, Masaki
    Tanino, Mishie
    Kitada, Masahiro
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2023, 15 (11)
  • [50] Randomized trial of preoperative docetaxel with or without capecitabine after 4 cycles of 5-fluorouracil-epirubicin-cyclophosphamide (FEC) in early-stage breast cancer: exploratory analyses identify Ki67 as a predictive biomarker for response to neoadjuvant chemotherapy
    Ohno, S.
    Chow, L. W. C.
    Sato, N.
    Masuda, N.
    Sasano, H.
    Takahashi, F.
    Bando, H.
    Iwata, H.
    Morimoto, T.
    Kamigaki, S.
    Nakayama, T.
    Nakamura, S.
    Kuroi, K.
    Aogi, K.
    Kashiwaba, M.
    Yamashita, H.
    Hisamatsu, K.
    Ito, Y.
    Yamamoto, Y.
    Ueno, T.
    Fakhrejahani, E.
    Yoshida, N.
    Toi, M.
    BREAST CANCER RESEARCH AND TREATMENT, 2013, 142 (01) : 69 - 80
12345